EC 200-353-2
Real‑world analysis of 544,103 adults with ASCVD followed up to four years; comparative non‑statin outcomes evidence to inform treatment choices and LDL‑C goal attainment.
Phase 1 data show 75% imaging response and deep PSA declines at 50 mg; most adverse events were mild–moderate and 50 mg will advance to Phase 2.
Phase 1b Heart-2: single IV base-editing dose gave dose-dependent, durable PCSK9/LDL-C reductions up to 18 months in HeFH/premature CAD; well tolerated; FDA Fast Track; Phase 2 planned.
PMMA porous fibers with controllable pores (several nm to ~1,000 nm) selectively capture high-MW pathogenic substances (autoantibodies, lipoproteins, exosomes), enabling blood purification and biopharma
